Company / R&D Expense
ARVINAS, INC. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$285.2M
FY2025
5-year range
$67.2M / $379.7M
FY2021-FY2025
Trend
-18.1%
vs FY2024
Sector context
#63 of 210
Health Care
What the data says
At $285M, ARVINAS, INC.'s r&d expense ranks #63 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 9 years, ranging from $29M in FY2017 to $380M in FY2023.
Based on SEC 10-K filings.
$285M in FY2025 with a 5-year CAGR of +21.3%.
Declined from $380M to $285M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +38.1%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Sector benchmark
#63 of 210 in Health CareTop 30% of 210This company $285.2M Sector average $644.1M
▼
-55.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 18.1% year-over-year.
- Ranks #63 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.85 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $285.2M | -18.1% |
| FY2024 | $348.2M | -8.3% |
| FY2023 | $379.7M | +250.3% |
| FY2022 | $108.4M | +61.3% |
| FY2021 | $67.2M | -38.0% |
| FY2020 | $108.4M | +139.9% |
| FY2019 | $45.2M | +0.0% |
| FY2018 | $45.2M | +57.0% |
| FY2017 | $28.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026